Cargando…

Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application

Natural coumarin derivatives and cyclometallic iridium (Ⅲ) (Ir(Ⅲ)) complexes have attracted much attention in the field of anticancer. In this study, six coumarin-modified cyclometallic Ir(Ⅲ) salicylaldehyde Schiff base complexes ([(ppy)(2)Ir(O^N)]/[(ppy-CHO)(2)Ir(O^N)]) were designed and synthesize...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ruixi, Wu, Yuting, Liu, Zhe, Liu, Jinfeng, Liu, Xicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127163/
https://www.ncbi.nlm.nih.gov/pubmed/35620650
http://dx.doi.org/10.3389/fchem.2022.906954
_version_ 1784712288880558080
author Xu, Ruixi
Wu, Yuting
Liu, Zhe
Liu, Jinfeng
Liu, Xicheng
author_facet Xu, Ruixi
Wu, Yuting
Liu, Zhe
Liu, Jinfeng
Liu, Xicheng
author_sort Xu, Ruixi
collection PubMed
description Natural coumarin derivatives and cyclometallic iridium (Ⅲ) (Ir(Ⅲ)) complexes have attracted much attention in the field of anticancer. In this study, six coumarin-modified cyclometallic Ir(Ⅲ) salicylaldehyde Schiff base complexes ([(ppy)(2)Ir(O^N)]/[(ppy-CHO)(2)Ir(O^N)]) were designed and synthesized. Compared with coumarin and Ir(Ⅲ) complex monomers, target complexes exhibited favorable cytotoxic activity toward A549 and BEAS-2B cells. These complexes could induce extensive apoptosis of A549 cell (late apoptosis), which was represented by the disturbance of cell cycle (G(1)-phase) and the accumulation of intracellular reactive oxygen species, exhibiting an anticancer mechanism of oxidation. With the help of suitable fluorescence of these complexes, no conflict with the probes, confocal detection confirmed that complexes showed an energy-dependent cellular uptake mechanism and triggered lysosome-mediated apoptosis in A549 cell line. Above all, our findings reveal the design of a lysosomal targeting cyclometallic Ir(Ⅲ) Schiff base complexes and provide a new idea for the design of integrated drugs for diagnosis and treatment.
format Online
Article
Text
id pubmed-9127163
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91271632022-05-25 Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application Xu, Ruixi Wu, Yuting Liu, Zhe Liu, Jinfeng Liu, Xicheng Front Chem Chemistry Natural coumarin derivatives and cyclometallic iridium (Ⅲ) (Ir(Ⅲ)) complexes have attracted much attention in the field of anticancer. In this study, six coumarin-modified cyclometallic Ir(Ⅲ) salicylaldehyde Schiff base complexes ([(ppy)(2)Ir(O^N)]/[(ppy-CHO)(2)Ir(O^N)]) were designed and synthesized. Compared with coumarin and Ir(Ⅲ) complex monomers, target complexes exhibited favorable cytotoxic activity toward A549 and BEAS-2B cells. These complexes could induce extensive apoptosis of A549 cell (late apoptosis), which was represented by the disturbance of cell cycle (G(1)-phase) and the accumulation of intracellular reactive oxygen species, exhibiting an anticancer mechanism of oxidation. With the help of suitable fluorescence of these complexes, no conflict with the probes, confocal detection confirmed that complexes showed an energy-dependent cellular uptake mechanism and triggered lysosome-mediated apoptosis in A549 cell line. Above all, our findings reveal the design of a lysosomal targeting cyclometallic Ir(Ⅲ) Schiff base complexes and provide a new idea for the design of integrated drugs for diagnosis and treatment. Frontiers Media S.A. 2022-05-10 /pmc/articles/PMC9127163/ /pubmed/35620650 http://dx.doi.org/10.3389/fchem.2022.906954 Text en Copyright © 2022 Xu, Wu, Liu, Liu and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Chemistry
Xu, Ruixi
Wu, Yuting
Liu, Zhe
Liu, Jinfeng
Liu, Xicheng
Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application
title Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application
title_full Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application
title_fullStr Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application
title_full_unstemmed Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application
title_short Lysosomal Targeted Cyclometallic Iridium(Ⅲ) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application
title_sort lysosomal targeted cyclometallic iridium(ⅲ) salicylaldehyde-coumarin schiff base complexes and anticancer application
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127163/
https://www.ncbi.nlm.nih.gov/pubmed/35620650
http://dx.doi.org/10.3389/fchem.2022.906954
work_keys_str_mv AT xuruixi lysosomaltargetedcyclometalliciridiumiiisalicylaldehydecoumarinschiffbasecomplexesandanticancerapplication
AT wuyuting lysosomaltargetedcyclometalliciridiumiiisalicylaldehydecoumarinschiffbasecomplexesandanticancerapplication
AT liuzhe lysosomaltargetedcyclometalliciridiumiiisalicylaldehydecoumarinschiffbasecomplexesandanticancerapplication
AT liujinfeng lysosomaltargetedcyclometalliciridiumiiisalicylaldehydecoumarinschiffbasecomplexesandanticancerapplication
AT liuxicheng lysosomaltargetedcyclometalliciridiumiiisalicylaldehydecoumarinschiffbasecomplexesandanticancerapplication